Long-acting Antiretrovirals for the Treatment and Prevention of HIV Infection: Promises and Pitfalls

Session Objectives:

• Explain the data on why long-acting agents for HIV are important.
• Discuss the data on long-acting cabotegravir/rilpivirine (CAB/RPV) fortreatment in those starting with and without virologic suppression.
• Review the data on long-acting cabotegravir for prevention.
• Discuss lenacapavir and its current and upcoming roles.
• Review the promises and pitfalls of long-acting agents for HIV.

Presented by:
Monica Gandhi MD, MPH
Professor of Medicine, and Associate Chief
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco